Aarti Drugs Limited (NSE:AARTIDRUGS)
India
· Delayed Price · Currency is INR | Market Cap | 43.68B |
| Revenue (ttm) | 23.87B |
| Net Income (ttm) | 1.68B |
| Shares Out | n/a |
| EPS (ttm) | 18.35 |
| PE Ratio | 25.97 |
| Forward PE | 20.59 |
| Dividend | 1.00 (0.21%) |
| Ex-Dividend Date | Feb 4, 2025 |
| Volume | 95,416 |
| Average Volume | 340,378 |
| Open | 478.00 |
| Previous Close | 475.05 |
| Day's Range | 475.40 - 480.55 |
| 52-Week Range | 312.00 - 635.00 |
| Beta | 0.41 |
| RSI | 58.43 |
| Earnings Date | Jul 24, 2025 |
About Aarti Drugs
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, moxifloxacin, norfloxacin, ofloxacin, metronidazole benzoate, ornidazole, secnidazole, ti... [Read more]
Financial Performance
In 2024, Aarti Drugs's revenue was 23.87 billion, a decrease of -5.60% compared to the previous year's 25.29 billion. Earnings were 1.68 billion, a decrease of -1.90%.
Financial StatementsNews
Aarti Drugs share price jumps 6% as Q4 EBITDA rises 8.9% YoY to Rs 93.4 crore
Aarti Drugs Ltd saw its shares jump 6% after the company reported a robust financial performance for the March quarter of FY25. As of 9:16 AM, the shares were trading 4.89% higher at Rs 367.00. The ph...
Aarti Drugs Q4 results: Revenue up 9.1% YoY to Rs 676.76 crore, Net profit rises 32% YoY
Aarti Drugs Limited reported its financial results for the fourth quarter ended March 31, 2025, showcasing a significant improvement in profitability. The company posted a consolidated net profit of ₹...
Aarti Drugs receives US FDA clearance, removed from Import Alert 66-40
Aarti Drugs Limited announced that it has successfully been removed from the United States Food and Drug Administration (US FDA) Import Alert 66-40, paving the way for the company to resume exports to...
Aarti Drugs Ltd (BOM:524348) Q3 2025 Earnings Call Highlights: Navigating Revenue Decline with ...
Aarti Drugs Ltd (BOM:524348) Q3 2025 Earnings Call Highlights: Navigating Revenue Decline with Strategic Investments and Operational Efficiency
Aarti Drugs shares surge despite Q3 FY25 EBITDA margin falls to 11.1%
Aarti Drugs Limited saw its shares rise 1.34% to ₹402.00 following the announcement of its Q3 FY25 financial results. The company reported a 1.1% year-on-year (YoY) growth in consolidated net profit, ...
Aarti Drugs Q3 FY25 results: Revenue down 8% to Rs 556.6 crore, Net Profit flat at Rs 37.09 crore
Aarti Drugs Limited has announced its consolidated financial results for Q3 FY25, reporting revenue from operations of ₹556.6 crore, marking a YoY decline of 8.1% from ₹606.94 crore in Q3 FY24 and a Q...
Aarti Drugs shares surge 15% after receiving EIR from USFDA for API plant in Tarapur
Aarti Drugs Limited witnessed a 15% surge in its stock price after receiving the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA). The EIR pertains to ...
Aarti Drugs shares fall over 2% following poor Q2 FY25 results
Aarti Drugs witnessed a decline of over 2% in its share price following the release of its financial results for the second quarter of FY25. The company’s performance showed a noticeable drop in both ...
Aarti Drugs stock in focus as Q2 FY25 results show 6.3% revenue decline to ₹543.09 crore; profit falls 12.1% YoY to ₹40.99 crore
Aarti Drugs Limited has announced its financial results for the second quarter of FY25, reporting a decrease in both revenue and profit compared to the same period in the previous year. Key Financial ...
Aarti Drugs Q2 FY25 Results: Revenue declines 6.3% YoY to Rs 543 crore, Profit falls 12% YoY
Aarti Drugs Limited has reported its financial results for the second quarter of FY25, showing a decline in both revenue and profit compared to the same period last year.
Aarti Drugs shares surge over 2% after arm gets GMP certificate from UK MHRA
Aarti Drugs shares jumped more than 2% in morning trade after its subsidiary, Pinnacle Life Science Private Limited, got a “Certificate of GMP Compliance of a Manufacturer” from the Medicines and Heal...
Aarti Drugs’ subsidiary Pinnacle Life Science receives GMP certificate from UK MHRA
Aarti Drugs Limited announced that its subsidiary, Pinnacle Life Science Private Limited, has received a “Certificate of GMP Compliance of a Manufacturer” from the Medicines and Healthcare products Re...
Aarti Drugs Buyback Opens Today, Set to Close on 18th September 2024
Aarti Drugs Ltd has announced the commencement of its share buyback today, 11th September 2024. The buyback issue will remain open until 18th September 2024, with the last date for payment considerati...